Equity Profile

ASND

Ascendis Pharma A/S

Health CareBiotechnology$16.2B

Aug13Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Ascendis Pharma A/S is a biotechnology company focused on developing innovative therapies for rare diseases and endocrine disorders. With a market cap of $16 billion, it operates in the health care sector, which is increasingly important as demand for specialized treatments grows.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS will indicate the company's profitability and performance compared to previous quarters.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and support future innovations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ASND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+528.60%

Avg Stock Reaction

+0.76%

Last Quarter Recap

In Q1-2026, Ascendis Pharma reported an impressive EPS of $11.46, significantly exceeding expectations. This marked a remarkable turnaround from previous quarters where the company faced losses.

Management Promises & Guidance

Focus on advancing pipeline products.
Commitment to improving operational efficiency.
Plans to enhance market access for key therapies.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has shown volatility in past earnings reports. Investors are keen to see if the positive momentum from last quarter can be sustained.

Bull Case

If Ascendis can replicate its last quarter's success, it may signal strong demand for its therapies and a solid growth trajectory.

Bear Case

On the other hand, if the company fails to meet or provide guidance on revenue and profitability, it could lead to a significant sell-off.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

A strong EPS could indicate sustained profitability and investor confidence, while a weak EPS could raise concerns about the company's future.

What guidance will management provide regarding revenue growth?

Clear guidance on revenue growth is essential for investors to assess the company's trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Ascendis to sustain its recent profitability, as the last quarter's EPS surprise suggests a strong product demand.

Supporting Evidence

The last quarter's EPS of $11.46 indicates a significant turnaround that could continue.

Options pricing suggests a higher expected move, indicating investor anticipation of further positive news.

Key Risk

If the EPS comes in below $1.00, it could undermine the recent positive sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Ascendis can maintain its recent positive momentum or if it will revert to previous losses.

Bull Confirmed If

An EPS of $11.00 or higher would confirm the bull case, indicating strong demand for Ascendis' products.

Bear Confirmed If

An EPS below $1.00 would confirm the bear case, suggesting ongoing challenges in achieving profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±9.25%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a considerable move, suggesting that investors expect significant volatility around the earnings report.

Options are pricing ±9.3% while ASND has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

41.3%

Calls (3K)P/C Ratio: 5.70Puts (200)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ascendis beats expectations, history suggests the stock could rise by around 4.71%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management is cautious, the stock may remain volatile as investors digest the commentary.

Miss

A miss could lead to a decline of approximately 1.60%, as it would raise concerns about the company's growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline products and their expected market launch dates.
2Details on operational efficiencies and cost management strategies.
3Management's outlook on market access for key therapies.
4Insights into competitive landscape and how Ascendis plans to differentiate its offerings.
5Any commentary on regulatory progress for upcoming therapies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS will indicate the company's profitability and performance compared to previous quarters.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and support future innovations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ASND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+528.60%

Avg Stock Reaction

+0.76%

Last Quarter Recap

In Q1-2026, Ascendis Pharma reported an impressive EPS of $11.46, significantly exceeding expectations. This marked a remarkable turnaround from previous quarters where the company faced losses.

Management Promises & Guidance

Focus on advancing pipeline products.
Commitment to improving operational efficiency.
Plans to enhance market access for key therapies.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has shown volatility in past earnings reports. Investors are keen to see if the positive momentum from last quarter can be sustained.

Bull Case

If Ascendis can replicate its last quarter's success, it may signal strong demand for its therapies and a solid growth trajectory.

Bear Case

On the other hand, if the company fails to meet or provide guidance on revenue and profitability, it could lead to a significant sell-off.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

A strong EPS could indicate sustained profitability and investor confidence, while a weak EPS could raise concerns about the company's future.

What guidance will management provide regarding revenue growth?

Clear guidance on revenue growth is essential for investors to assess the company's trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Ascendis to sustain its recent profitability, as the last quarter's EPS surprise suggests a strong product demand.

Supporting Evidence

The last quarter's EPS of $11.46 indicates a significant turnaround that could continue.

Options pricing suggests a higher expected move, indicating investor anticipation of further positive news.

Key Risk

If the EPS comes in below $1.00, it could undermine the recent positive sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Ascendis can maintain its recent positive momentum or if it will revert to previous losses.

Bull Confirmed If

An EPS of $11.00 or higher would confirm the bull case, indicating strong demand for Ascendis' products.

Bear Confirmed If

An EPS below $1.00 would confirm the bear case, suggesting ongoing challenges in achieving profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±9.25%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a considerable move, suggesting that investors expect significant volatility around the earnings report.

Options are pricing ±9.3% while ASND has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

41.3%

Calls (3K)P/C Ratio: 5.70Puts (200)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ascendis beats expectations, history suggests the stock could rise by around 4.71%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management is cautious, the stock may remain volatile as investors digest the commentary.

Miss

A miss could lead to a decline of approximately 1.60%, as it would raise concerns about the company's growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline products and their expected market launch dates.
2Details on operational efficiencies and cost management strategies.
3Management's outlook on market access for key therapies.
4Insights into competitive landscape and how Ascendis plans to differentiate its offerings.
5Any commentary on regulatory progress for upcoming therapies.